Drug Candidates

15 candidates mapped to SDH-deficient disease pathways

All (15)established (4)clinical trial (2)preclinical (6)theoretical (3)
Belzutifan

Welireg

established

HIF-2α inhibitor

Hif Pseudohypoxia
Evidence Score
82
FDA Approved
Sunitinib

Sutent

established

Multi-kinase inhibitor (VEGFR/PDGFR/KIT)

Vegf SignalingMtor Pi3k Akt
Evidence Score
75
FDA Approved
Temozolomide

Temodar, Temodal

clinical trial

Alkylating agent

Epigenetic Dysregulation
Evidence Score
68
FDA Approved
Bevacizumab

Avastin

established

Anti-VEGF monoclonal antibody

Vegf Signaling
Evidence Score
65
FDA Approved
Telaglenastat

CB-839

clinical trial

Glutaminase inhibitor

Glutamine Dependency
Evidence Score
60
Regorafenib

Stivarga

established

Multi-kinase inhibitor (VEGFR/KIT/PDGFR/FGFR/RAF)

Vegf SignalingMtor Pi3k Akt
Evidence Score
58
FDA Approved
Everolimus

Afinitor

preclinical

mTOR inhibitor (rapalog)

Mtor Pi3k Akt
Evidence Score
55
FDA Approved
Azacitidine

Vidaza

preclinical

DNA methyltransferase inhibitor (hypomethylating agent)

Epigenetic Dysregulation
Evidence Score
52
FDA Approved
Decitabine

Dacogen

preclinical

DNA methyltransferase inhibitor (hypomethylating agent)

Epigenetic Dysregulation
Evidence Score
50
FDA Approved
Olaparib

Lynparza

theoretical

PARP inhibitor

Oxidative Stress Ros
Evidence Score
45
FDA Approved
Metformin

Glucophage

preclinical

Biguanide / Complex I inhibitor / AMPK activator

Mtor Pi3k AktOxidative Stress Ros
Evidence Score
40
FDA Approved
Ascorbic Acid (High-dose IV)
preclinical

TET enzyme cofactor / α-KG-dependent dioxygenase activator

Epigenetic DysregulationOxidative Stress Ros
Evidence Score
38
Dichloroacetate (DCA)
preclinical

Pyruvate dehydrogenase kinase inhibitor

Hif PseudohypoxiaOxidative Stress Ros
Evidence Score
35
Panobinostat

Farydak

theoretical

Pan-HDAC inhibitor

Epigenetic Dysregulation
Evidence Score
30
FDA Approved
Enasidenib

Idhifa

theoretical

IDH2 inhibitor

Epigenetic Dysregulation
Evidence Score
28
FDA Approved